Skip to main content


  • Poster presentation
  • Open Access

No effect of a single supratherapeutic dose of lersivirine, a next-generation NNRTI, on QTc interval in healthy subjects

  • 1,
  • 1,
  • 2,
  • 3 and
  • 3
Journal of the International AIDS Society201013 (Suppl 4) :P225

  • Published:


  • Placebo
  • Moxifloxacin
  • Regulatory Threshold
  • Supratherapeutic Dose
  • Adverse Event Monitoring

Purpose of the study

Lersivirine (LRV) is a next-generation NNRTI currently under investigation in two Phase IIb studies at doses of 500 - 1000 mg QD. In vitro analyses suggest that LRV is a weak Ikr and CA2+ channel blocker. However, dose-ranging Phase I studies have not shown prolongation of QTc interval to date. This study was performed to investigate the effect of a supratherapeutic dose of LRV on QTc interval in healthy subjects, relative to matched placebo and active control.


A randomized, single-dose, placebo- and active-controlled 3-way crossover study was performed with 48 healthy adults. Subjects were randomized to receive either LRV (2400 mg), moxifloxacin (400 mg) or placebo for each treatment period with minimum washout of 7 days. Triplicate 12-lead electrocardiogram (ECG) measurements were performed and PK samples collected predose and at 1, 2, 3, 4, 5, 6, 9, 12, and 24 hrs postdose. Vital signs were measured predose, 3 hrs postdose and at discharge. Adverse event monitoring and safety laboratory testing were performed throughout.

Summary of results

All 48 subjects enrolled were white males (mean age 39.1 yrs, body mass index 25.6 kg/m2) and completed the study. Following LRV administration, the upper bound of 90% CI for time-matched adjusted mean differences to placebo in QTcF at each of the time points postdose was below the regulatory threshold of 10 msec, thus satisfying the criteria for a negative thorough QT/QTc study. The highest upper bound of 90% CI occurred at 6 hrs for LRV (3.32, 90% CI 1.5, 5.1). The study was deemed adequately sensitive as the lower bound of the 90% CI for the adjusted mean differences between moxifloxacin and placebo at moxifloxacin's historical Tmax of 3 hrs was >5 msec (15.29 msec, 90% CI: 13.5, 17.1 msec). No subjects receiving LRV or placebo had a QTcF ≥450 msec, nor did any experience a QTcF increase ≥30 msec from baseline at any time point. In subjects receiving LRV, no clinically significant changes in QRS complex, PR interval, heart rate or blood pressure were observed. PK analysis of blood samples indicated geometric mean (CV%) AUClast 17750 (28%) and Cmax 1727 ng/mL (33%), and median Tmax 3 hrs. Adverse events were generally mild, with some moderate gastrointestinal events.


LRV administered as a single 2400 mg supratherapeutic dose did not prolong the QTc interval and no clinically relevant ECG or vital sign changes were observed in healthy subjects.

Authors’ Affiliations

Pfizer Global Research and Development, New London, USA
Pfizer Research Clinic, Brussels, Belgium
Pfizer Global Research and Development, 50 Pequot Avenue, New London, USA


© Vourvahis et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.